Japanese stock market research agency Harver Group today announced the appointment of Mr. Stephen Rogers as an Executive Director on the company’s Board of Directors.
Spokesperson Mr. Peter Williams at the Tokyo based investment research firm Harver Group this morning announced at an investor meeting, that Mr. Stephen Rogers, who currently serves with Harver Group as the Director of Private Equity, will as of today also serve as an Executive on the company’s board of directors. His newly undertaken role will see Mr. Rogers contribute to board room policy making, corporate governance and other compliance related matters.
Mr. Rogers who graduated from the Oxford University in the United Kingdom, before returning to study at the London School Of Economics, and finally beginning his career within the UK banking industry. He has worked with Harver Group for almost 10 years now, and his appointment to the board of directors reflects those years of loyal service, his technical expertise, and his excellent performance within the markets over that period.
Mr. Nathan Bradley, Head of Investment Analysis at Harver Group said “I’ve personally worked with Stephen for many years, and he has outperformed the markets and his competitor’s year in year out, so I can think of no one who deserves the appointment more than he does.”
Despite his appointment to this new position, Mr. Rogers will continue to work in his current role as Director of Private Equity on a daily basis for at least the next 5 years until the end of the term of his contract, and will of course maintain his current client portfolio himself. For his client base therefore, there will be no immediate changes.
Mr. Rogers himself also commented upon his appointment saying “I’m certainly very pleased and honored to have had my efforts recognized, and I will deliver the results expected of me.”
Keywords: Stephen Rogers, harvergroup.com, Harver Group
By: Harver Group
Article Directory: http://www.articlecatalog.com
Copy and Paste Link Code:
Read other Articles from Harver Group:
- Harver Group Long On Asian Stocks as US Job Market Improves
- Harver Group Delegation to Attend AsFA Annual Meeting
- Harver Group to Host Open Day at Hong Kong Branch
- Harver Group to Recruit 80 Market Analysts for Hong Kong Branch
- Harver Group To Invest In Japan Following Weak Economic Data
Article ID 1008141 (Views 1331)
Announcement from Our Sponsor
Cancer Drugs like Lenvima (generic version Lenvatinib), Imbruvica (generic version Ibrutinib) now have generic versions at tremendous savings. Brain boosting drugs like Provigil (generic version Modafinil) and Nuvigil (generic version Armodafinil) are also popular.